Incyte share price logo

Incyte

NASDAQ: INCY

Large Cap

$127.23

-1.23

(-0.96%)

as on

Incyte Stock Performance

as on August 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $126.71
    $129.80
    downward going graph

    0.41%

    Downside

    2.02%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $81.09
    $132.60
    downward going graph

    36.27%

    Downside

    4.22%

    Upside

    downward going graph

Incyte share price movements today

Previous Close
$128.47
Open
$127.10
Volume
721.3K
Market Cap
$24.4B
Day's Low - High
$126.71 - $129.80
52 Week Low - High
$81.09 - $132.60

Incyte Historical Returns

1 Month Return
+ 2.48 %
3 Month Return
+ 26.07 %
1 Year Return
+ 38.24 %
3 Year Return
+ 87.14 %
5 Year Return
+ 58.82 %

Incyte Stock Fundamentals & Key Indicators

Check Incyte market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$24.4B

EPS (TTM)

8.13

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.38%

PE Ratio (TTM)

14.82

Industry PE ratio

10.197

PEG Ratio

0.1837699368729223

EBITDA

2.0B

Revenue (TTM)

5.8B

Profit Margin

92.62%

Return On Equity TTM

29.70%

Incyte Stock Valuation

Track how Incyte P/E has moved over time to understand its valuation trends.

Incyte in the last 5 years

  • Overview

  • Trends

Lowest (14.99x)

December 31, 2025

Industry (10.20x)

December 31, 2025

Today (14.99x)

December 31, 2025

Highest (431.69x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 14.99x

Incyte vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Incyte with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$24.4B58.82%14.8292.62%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Incyte Stock including INR - Dollar returns

The Incyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Incyte investment value today

Current value as on today

₹1,60,972

Returns

₹60,972

(+60.97%)

Returns from Incyte Stock

₹46,376 (+46.38%)

Dollar Impact

₹14,596 (+14.6%)

Analyst Recommendation on Incyte Stock

Based on 20 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 20 analysts, 50% of analysts recommend a 'BUY' rating for Incyte. Average target price of $125.17

Incyte Share Price Target

Get share price movements and forecasts by analysts on Incyte.

What analysts predicted

-1.65%DOWNSIDE

Target Price

$125.17

Current Price

$127.23

Analyzed by

20 Analysts

Target

$125.17

Incyte target price $125.17, a slight downside of -1.65% compared to current price of $127.23. According to 20 analysts rating.

Indian Investors' Interest in Incyte Stock

Search interest for Incyte Stock has increased by 8% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:8% versus previous 30 day period

Incyte Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
880
1,043
1,137
1,178
1,052
1,215
1,365
1,506
1,272
1,674
Gross Profit
819
967
1,051
1,090
979
1,136
1,266
1,385
1,168
1,569
Operating Income
91
-478
146
297
216
310
431
383
324
697
EBITDA
258
-367
179
336
257
581
506
414
367
752
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
21
22
22
22
22
22
24
23
23
-
Income Before Tax
236
-389
156
313
234
558
482
389
343
751
Income Tax Expense
66
54
50
112
75
153
58
90
40
165
Net Income
169
-444
106
201
158
404
424
299
303
585
Net Profit Margin
91.24%
91.09%
91.00%
92.49%
93.05%
93.52%
92.75%
91.96%
91.79%
93.73%

Incyte Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,536
1,881
2,158
2,666
2,986
3,394
3,695
4,241
5,141
Gross Profit
1,456
1,787
2,044
2,535
2,835
3,187
3,440
3,929
4,769
Operating Income
-243
129
402
-263
585
591
655
101
1,342
EBITDA
-253
171
543
-178
630
599
919
408
1,760
Interest Expense
6
1
1
2
1
2
2
2
2
Depreciation
52
54
54
51
57
67
82
89
93
Income Before Tax
-312
115
486
-232
570
529
834
316
1,664
Income Tax Expense
0
5
39
63
-378
188
236
284
377
Net Income
-313
109
446
-295
948
340
597
32
1,286
Net Profit Margin
92.83%
93.22%
93.18%
93.94%
93.73%
92.54%
91.47%
92.64%
92.76%

Incyte Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
169
-444
106
201
158
404
424
299
303
585
Operating Cash Flow
218
-575
310
381
266
44
559
543
369
507
Investing Cash Flow
-73
213
38
-21
1
-18
-47
-37
-88
-51
Financing Cash Flow
-12
-1,997
-32
20
-12
-11
-12
137
84
65
Change in Cash
132
-2,358
316
383
253
13
500
642
363
521

Incyte Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-313
109
446
-295
948
340
597
32
1,286
Operating Cash Flow
-92
336
710
-124
749
969
496
335
1,413
Investing Cash Flow
-349
-86
-87
-269
-207
-78
-207
157
-102
Financing Cash Flow
690
14
45
71
6
0
-20
-2,021
101
Change in Cash
247
264
668
-318
544
893
262
-1,525
1,410

Mutual Funds that own Incyte Stock

Check out the Mutual Funds with significant holdings in Incyte.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.749227%
15707509
Dodge & Cox Funds
4.862317%
9855808
Fidelity Concord Street Trust
1.436546%
2911847
VANGUARD SPECIALIZED FUNDS
1.167067%
2365620
VANGUARD INSTITUTIONAL INDEX FUNDS
0.505113%
1023854

Global Institutional Holdings in Incyte

Funds
Holdings
Amundi
0.36%
Felix Baker
15.17%
Vanguard
8.66%
iShares
6.44%
John A. Gunn
5.9%

Incyte News & Key Events

    Insights on Incyte

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 2 quarters, 1.27B → 1.67B (in $), with an average increase of 24.0% per quarter

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 3 quarters, 299.27M → 585.60M (in $), with an average increase of 24.8% per quarter

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, INCY stock has moved up by 6.6%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Revolution Medicines, Inc. Common Stock has given 624.7% return, outperforming this stock by 524.1%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.6% return, outperforming this stock by 444.6%

    About Incyte

    Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
    OrganisationIncyte
    Headquarters1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
    IndustryBiotechnology
    CEOMr. William J. Meury
    E-voting on sharesClick here to vote

    Key Management of Incyte

    Name

    Title

    Mr. Richard A. Hoffman J.D., M.B.A.

    Executive VP, General Counsel & Secretary

    Ms. Pamela M. Murphy

    VP of Investor Relations & Corporate Communications

    Dr. Steven H. Stein M.D.

    Executive VP, Head of Late-stage Development & Chief Medical Officer

    Mr. Mohamed Khairie Issa

    Executive Vice President & Head of U.S. Commercial

    Mr. Suketu P. Upadhyay

    Executive VP & CFO

    Mr. Michael James Morrissey

    Executive VP & Head of Global Technical Operations

    Ms. Alexis Smith

    VP & Head of Investor Relations

    Mr. William J. Meury

    CEO & Director

    Dr. Pablo J. Cagnoni M.D., Ph.D.

    President and Global Head of R&D

    Mr. Thomas Tray

    Principal Financial Officer, VP of Finance & Chief Accounting Officer

    FAQs

    What is Incyte share price today?

    Incyte share price today is $127.23 as on at the close of the market. Incyte share today touched a day high of $129.80 and a low of $126.71.

    What is the 52 week high and 52 week low for Incyte share?

    Incyte share touched a 52 week high of $132.60 on and a 52 week low of $81.09 on . Incyte stock price today i.e. is closed at $127.23,which is 4.05% down from its 52 week high and 56.90% up from its 52 week low.

    What is Incyte's market capitalisation today?

    Incyte market capitalisation is $0.02T as on .

    How to invest in Incyte Stock (INCY) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Incyte on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Incyte Shares that will get you 0.0118 shares as per Incyte share price of $127.23 per share as on August 21, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Incyte Stock (INCY) from India?

    Indian investors can start investing in Incyte (INCY) shares with as little as ₹95.695 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹956.95 in Incyte stock (as per the Rupee-Dollar exchange rate as on ). Based on Incyte share’s latest price of $127.23 as on August 21, 2026 at 1:29 am IST, you will get 0.0786 shares of Incyte. Learn more about fractional shares .

    What are the returns that Incyte has given to Indian investors in the last 5 years?

    Incyte stock has given 58.82% share price returns and 28.59% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?